CD274 and non-small cell lung carcinoma: In EMPOWER-Lung 1, a multicenter trial which examined cemiplimab of advanced NSCLC with PD-L1 of at least 50%, cemiplimab significantly improved OS and PFS compared with chemotherapy [145].